Page 3 - Agrx News Today

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.22 and traded as high as $0.30. Agile Therapeutics shares last traded at $0.29, with a volume of 576,188 shares. Wall Street Analyst Weigh In Separately, StockNews.com initiated […]

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 502,600 shares, a growth of 126.7% from the May 15th total of 221,700 shares. Approximately 11.4% of the shares of the stock are sold short. Based on […]

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 221,700 shares, a drop of 22.7% from the April 30th total of 286,900 shares. Currently, 5.0% of the company’s shares are short sold. Based […]

StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. Several other research analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Agile Therapeutics […]

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) has been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among […]

Agile Therapeutics (NASDAQ:AGRX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday, Zacks.com reports. According to Zacks, “Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The […]

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) – Stock analysts at Oppenheimer lifted their Q2 2022 earnings per share (EPS) estimates for shares of Agile Therapeutics in a research report issued to clients and investors on Thursday, March 31st. Oppenheimer analyst L. Gershell now forecasts that the specialty pharmaceutical company will post earnings of ($0.10) […]

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 1,910,000 shares, an increase of 34.5% from the February 28th total of 1,420,000 shares. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 1.7 days. […]

Zacks Investment Research upgraded shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) from a sell rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports. According to Zacks, “Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive […]

Equities analysts predict that Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) will report ($0.17) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Agile Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.20). Agile […]